Table 2.

Association Statistics for Top Variant at Each Genome-Wide Significant Locus

Chr	Position (hg19)	rsID	Risk/Alt Allele	RAF	Unadjusted P Value	HR	Adjusted P Value	Adjusted HR	% Genotyped	Annotation
10	114754071	rs34872471	C/T	0.30	2.80e-12	1.51	1.30e-12	1.53	0%	TCF7L2
10	114758349	rs7903146	T/C	0.30	4.88e-12	1.50	2.54e-12	1.52	100%	TCF7L2
1	205914757	rs4077468	A/G	0.59	2.25e-8	1.38	4.12e-8	1.38	95.8%	SLC26A9
2	232560638	rs838455	T/C	0.08	2.98e-8	1.75	7.60e-8	1.74	0%	PTMA
2	232572011	rs838440	G/T	0.09	3.45e-8	1.69	8.44e-8	1.69	100%	PTMA

CFRD onset was analyzed as a censored trait (event = diagnosis of diabetes; censoring = age at last normal diabetes screening test). Unadjusted analysis includes adjustment for 4 principal components and site. Adjusted analysis also includes sex as a covariate. Frailty model was used to account for relatedness. Three loci were genome-wide significant (P value < 5e-8). The most significantly associated variants at each locus and the most significant genotyped variants at each locus are listed.

Abbreviations: % genotyped, percent of individuals who have been genotyped at this locus, as opposed to being imputed; Chr, chromosome; HR, hazard ratio; RAF, risk allele frequency.